my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
08-12-2006: elbion AG announced it has merged with 4AZA Bioscience NV, Belgium, to form a European company for discovery and development of drugs for CNS and immunological diseases. The combined company, to be called elbion NV ("elbion"), will be headquartered at 4AZA's current site in Leuven, where it will concentrate its corporate functions, business development activities and its research facilities for immunology. elbion AG's facilities and staff in Radebeul will be retained and continue to drive the largest part of the company's fully integrated drug discovery and development activity.
Bernd Kastler, CEO of elbion AG will be CEO of the combined group and will re-locate to Leuven and be joined by Thomas Taapken as CFO and Thomas Kronbach as CSO. Mark de Boer, former CEO of 4AZA will remain with elbion as a consultant to the company.
elbion's board includes Ann F. Hanham (Burrill & Company), Alexander Asam (Deutsche Venture Capital), Stephen Evans-Freke (independent board member), Luc Philips (independent board member), Staf Van Reet (independent board member), Christoph Schröder (TVM Capital), Klaus Stöckemann (3i), Claude Stoufs (Capricorn) and Bernd Kastler who acts as interim Chairman.
Watchlist
This is where you can add this news to your personal favourites
Biotie Therapies completes acquisition of pharmaceutical development company elbion
Biotie Therapies Corp. has entered into an agreement with elbion NV on the acquisition of its fully owned subsidiary, elbion GmbH. To complete the transaction, the Board of Directors of Biotie has proposed to the General Meeting of Shareholders of Biotie to be convened on 14 November 2008 t ... more
Biotie to acquire neurology and immunology focussed pharmaceutical company elbion GmbH
Biotie Therapies has entered into an agreement to acquire the German pharmaceutical company elbion GmbH. The combination of the two businesses will take place by a share exchange and create a leading European company in the field of discovery and development of therapeutics for central nerv ... more
elbion Merges With 4AZA to Form European Drug Discovery and Development Company
elbion AG announced it has merged with 4AZA Bioscience NV, Belgium, to form a European company for discovery and development of drugs for CNS and immunological diseases. The combined company, to be called elbion NV ("elbion"), will be headquartered at 4AZA's current site in Leuven, where it ... more
elbion Merges With 4AZA to Form European Drug Discovery and Development Company
elbion AG announced it has merged with 4AZA Bioscience NV, Belgium, to form a European company for discovery and development of drugs for CNS and immunological diseases. The combined company, to be called elbion NV ("elbion"), will be headquartered at 4AZA's current site in Leuven, where it ... more
4AZA Bioscience announces research collaboration with Gilead
4AZA Bioscience NV announced that the company has entered into a licensing agreement with Gilead Sciences to research and develop compounds for the potential treatment of hepatitis C virus (HCV) infection, a therapeutic area representing a significant unmet medical need. These compounds, di ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
